TABLE 5.
Goodness-of-fit, predictive performance (population predictions) and individual AUC24–48 from the six models in the final analysis (n = 78 patients, 376 vancomycin concentrations)
| Model | AIC | Weighted error (mg/liter) | Weighted squared error (mg2/liter2) | Individual AUC24–48 (mg · h · liter−1) |
|---|---|---|---|---|
| CG | 2,126.9 | 0.41 ± 4.6 | 21.6 ± 42.0 | 393 ± 167 |
| JEL | 2,097.2 | −0.49 ± 5.1 | 26.2 ± 61.3 | 373 ± 163 |
| MDRD | 2,101.2 | 1.1 ± 5.3 | 29.0 ± 67.3 | 391 ± 162 |
| MDRDm | 2,088.9 | 1.6 ± 5.2 | 29.8 ± 62.4 | 402 ± 169 |
| CKDEPI | 2,140.9 | 0.88 ± 4.6 | 22.2 ± 49.6 | 384 ± 162 |
| CKDEPIm | 2,126.9 | 1.3 ± 4.8 | 24.9 ± 52.4 | 385 ± 160 |
| P value | 0.0004a | 0.80a | 0.0002b |
a
Probability that the errors are not different among the models, using the Kruskal-Wallis test.
b
Probability that the individual AUCs calculated on the second day of therapy from each model are not significantly different, using the Friedman test.